Please login to the form below

Not currently logged in
Email:
Password:

lesinurad

This page shows the latest lesinurad news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s rare blood disorder drug Cablivi set for European approval

Sanofi’s rare blood disorder drug Cablivi set for European approval

In addition to the orphan drug approvals, the CHMP also gave positive opinions to Gruenenthal’s gout treatment Duzallo (lesinurad/allopurinol), a follow-up to the company’s Zurampic (lesinurad) product.

Latest news

More from news
Approximately 8 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Deal Watch October 2016 Deal Watch October 2016

    Gout 2016. Ironwood. Lesinurad US. $265m royalties. Rhinitis 2016. Janssen. Rhinocort outside US.

  • Deal Watch June 2016 Deal Watch June 2016

    The deal also covers a fixed dose combination of lesinurad and allopurinol which is currently in clinical trials. ... licence. 270. AstraZeneca/ Grünenthal. Zurampic (lesinurad) and lesinurad fixed-dose combo with allopurinol for hyperuricaemia in

  • Deal Watch April 2016 Deal Watch April 2016

    450. AstraZeneca (UK). Ironwood (US). US license and commercialisation. Lesinurad (approved) combo in development for treatment of gout.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics